The global gram-positive bacterial infections market size is expected to hit around US $ 58.76 billion by 2027 and projected to expand at a CAGR of 2.3% from 2020 to 2027.
The gram-positive bacterial infections market is projected to expand during the forecast period owing to an increase in the number of cases of gram-positive bacterial infections and rapid rise in antibacterial resistance. Moreover, factors such as increased government initiatives and funding for R&D activities & newer bacterial infection treatment and infection control in healthcare settings drive the global gram-positive bacterial infections market. North America dominated the global gram-positive bacterial infections market and is expected to maintain its position owing to a rise in the prevalence of bacterial infections, better diagnosis, and treatment rate in the region. Asia Pacific is a lucrative market for gram-positive bacterial infections. The market in Asia Pacific is expected to expand at a CAGR of 1.9% during the forecast period.
Increasing rate of gram-positive bacterial infections and rising antibacterial resistance to drive the global market
Rise in the number of infection cases due to gram positive bacteria is a major factor driving the global gram-positive bacterial infections market. These infections are more prevalent in recent times, which need better antibacterial drugs to cure. For instance, according to the study done by team of scientists from the University of Oxford, U.K. and the NHS Foundation Trust, U.K., cases of community-acquired pneumonia increased by 4% between 1998 and 2008 and 8% between 2008 and 2014, respectively. Rapid rise in antibacterial resistance and infection control in health care settings is also boosting the global market. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC) estimates, antibacterial resistance is responsible for over 2 million infections and 23,000 deaths in the U.S. each year. Similarly, increased government initiatives for newer bacterial infection drug discoveries is also major driver of the global gram-positive bacterial infections market.
Antibiotic to be dominant segment
Antibiotic is a dominant segment of the gram-positive bacterial infections market. It is expected to maintain its position and account for 62.3% share of the market by 2027, expanding at a CAGR of 1.5% between 2020 and 2027. The segment is anticipated to reach a value of US $ 36,535.9 Mn by 2027. Efficacy of antibiotics in treating a wide spectrum of bacterial infections and development of novel approaches for new antibiotics are likely to propel the segment of the global market during the forecast period.
Otitis segment to be highly lucrative
Sinusitis was a dominant segment of the gram-positive bacterial infections market in 2017. It is expected to maintain its position and hold 43.4% share of the market by the end of 2027. The otitis segment is anticipated to reach a value of US $ 2,252 Mn by 2027. It is projected to account for 3.8% share of the market by 2027 and expand at a CAGR of 3.3% during the forecast period. Otitis is a highly lucrative segment due to a rise in the prevalence of otitis media and the efficacy and safety of antibacterial agents to cure the infection.
Enteral segment dominated the global market
In terms of route of administration, the global market has been segmented into enteral, parenteral and others. The enteral segment held a major market share of the global market in 2019. It is anticipated to expand and account for a prominent share of the market during the forecast period. The enteral segment is projected to hold 66.8% share by 2027. The others segment is likely to expand at a CAGR of 2.2% during the forecast period. Expansion of this segment can be attributed to ease of use, lower risk of developing bacterial resistance, and higher concentrations in infected areas.
Drug stores and retail pharmacies to be lucrative distribution channel segment
In terms of distribution channel, the global market has been classified into hospital pharmacies, drug stores and retail pharmacies, and others. The drug stores and retail pharmacies segment held a major share of the global market in 2019. It is estimated to expand and hold a prominent share of the global market during the forecast period. The drug stores and retail pharmacies segment is projected to account for 57.7% share of the market by 2027 and expand at a CAGR of 1.9% during the forecast period. However, the others segment, which consists of online pharmacies, mail pharmacies and home care pharmacies, is more lucrative segment. It is expected to expand at a higher CAGR of 2.5% during the forecast period due to better discounted rates on drug purchase and convenience offered by online pharmacies.
North America expected to dominate global market
In terms of region, the global gram-positive bacterial infections market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017. The market in North America is projected to expand at a CAGR of 1.4% between 2020 and 2027. In terms of revenue, the market in North America was valued at US$ 19,222.8 Mn and the region held 37.5% share of the global market in 2019. This was due to a rise in the prevalence of bacterial infections, better diagnosis and treatment rate, and presence of major players in the region. The antibiotic segment dominated the market in the region. It is estimated to expand at a CAGR of 1.3% during the same period. Asia Pacific is projected to be a highly lucrative market and expand at a CAGR of 2.1% during the forecast period due to larger patient pool with bacterial infection, generic drug availability, and increase in awareness about various infections among the people in the region.
Bayer AG and Pfizer Inc. among major players in global market
The global gram-positive bacterial infections market is fragmented in terms of number of players. Key players operating in the global market include Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc. R&D activities, more product pipelines, and merger & acquisitions with local players are major strategies adopted by these players in the global market.
The report analyzes and forecasts the gram-positive bacterial infections market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of gram-positive bacterial infections, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major gram-positive bacterial infections companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of gram-positive bacterial infections upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of gram-positive bacterial infections and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global gram-positive bacterial infections market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the gram-positive bacterial infections market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of gram-positive bacterial infections market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report concludes with the company profiles section that includes key information about the major players in the market. Key players identified in this report are Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc. Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, Business segments and recent developments.
The global gram-positive bacterial infections market has been segmented as follows:
By Drug Type
By Disease
By Route of Administration
By Distribution Channel
Global Gram-positive Bacterial Infections Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Gram-positive Bacterial Infections Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Global Gram-positive Bacterial Infections Market Taxonomy
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gram-positive Bacterial Infections Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Patent Landscape
5.2. Key Success Factors of Top Players
5.3. Branded vs. Generic Drugs Overview
6. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
6.3.1. Antibiotic
6.3.1.1. B-Lactam
6.3.1.2. Quinolones
6.3.1.3. Macrolides
6.3.1.4. Tetracyclines
6.3.1.5. Aminoglycosides
6.3.1.6. Sulfonamides
6.3.1.7. Phenicols
6.3.1.8. Others
6.3.2. Antifungal
6.3.3. Others
6.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type
7. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
7.3.1. MRSA
7.3.2. Pneumonia
7.3.3. Sepsis
7.3.4. Sinusitis
7.3.5. Cellulitis
7.3.6. Otitis
7.3.7. Pharyngitis
7.3.8. Impetigo
7.3.9. Others
7.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Drug Type
8. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
8.3.1. Enteral
8.3.2. Parenteral
8.3.3. Others
8.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Route of Administration
9. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Drug Stores and Retail Pharmacies
9.3.3. Others
9.4. Global Gram-positive Bacterial Infections Market Attractiveness, by Distribution Channel
10. Global Gram-positive Bacterial Infections Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Gram-positive Bacterial Infections Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Gram-positive Bacterial Infections Market Attractiveness, by Region
11. North America Gram-positive Bacterial Infections Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
11.2.1. Antibiotic
11.2.1.1. B-Lactam
11.2.1.2. Quinolones
11.2.1.3. Macrolides
11.2.1.4. Tetracyclines
11.2.1.5. Aminoglycosides
11.2.1.6. Sulfonamides
11.2.1.7. Phenicols
11.2.1.8. Others
11.2.2. Antifungal
11.2.3. Others
11.3. North America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
11.3.1. MRSA
11.3.2. Pneumonia
11.3.3. Sepsis
11.3.4. Sinusitis
11.3.5. Cellulitis
11.3.6. Otitis
11.3.7. Pharyngitis
11.3.8. Impetigo
11.3.9. Others
11.4. North America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
11.4.1. Enteral
11.4.2. Parenteral
11.4.3. Others
11.5. North America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
11.5.1. Hospital Pharmacies
11.5.2. Drug Stores and Retail Pharmacies
11.5.3. Others
11.6. North America Gram-positive Bacterial Infections Market Value Forecast, by Country, 2016–2026
11.6.1. U.S.
11.6.2. Canada
11.7. North America Gram-positive Bacterial Infections Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Disease
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Gram-positive Bacterial Infections Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
12.2.1. Antibiotic
12.2.1.1. B-Lactam
12.2.1.2. Quinolones
12.2.1.3. Macrolides
12.2.1.4. Tetracyclines
12.2.1.5. Aminoglycosides
12.2.1.6. Sulfonamides
12.2.1.7. Phenicols
12.2.1.8. Others
12.2.2. Antifungal
12.2.3. Others
12.3. Europe Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
12.3.1. MRSA
12.3.2. Pneumonia
12.3.3. Sepsis
12.3.4. Sinusitis
12.3.5. Cellulitis
12.3.6. Otitis
12.3.7. Pharyngitis
12.3.8. Impetigo
12.3.9. Others
12.4. Europe Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
12.4.1. Enteral
12.4.2. Parenteral
12.4.3. Others
12.5. Europe Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
12.5.1. Hospital Pharmacies
12.5.2. Drug Stores and Retail Pharmacies
12.5.3. Others
12.6. Europe Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Europe Gram-positive Bacterial Infections Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Disease
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Gram-positive Bacterial Infections Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
13.2.1. Antibiotic
13.2.1.1. B-Lactam
13.2.1.2. Quinolones
13.2.1.3. Macrolides
13.2.1.4. Tetracyclines
13.2.1.5. Aminoglycosides
13.2.1.6. Sulfonamides
13.2.1.7. Phenicols
13.2.1.8. Others
13.2.2. Antifungal
13.2.3. Others
13.3. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
13.3.1. MRSA
13.3.2. Pneumonia
13.3.3. Sepsis
13.3.4. Sinusitis
13.3.5. Cellulitis
13.3.6. Otitis
13.3.7. Pharyngitis
13.3.8. Impetigo
13.3.9. Others
13.4. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
13.4.1. Enteral
13.4.2. Parenteral
13.4.3. Others
13.5. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
13.5.1. Hospital Pharmacies
13.5.2. Drug Stores and Retail Pharmacies
13.5.3. Others
13.6. Asia Pacific Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of APAC
13.7. Asia Pacific Gram-positive Bacterial Infections Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Disease
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Gram-positive Bacterial Infections Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Drug Type,2016–2026
14.2.1. Antibiotic
14.2.1.1. B-Lactam
14.2.1.2. Quinolones
14.2.1.3. Macrolides
14.2.1.4. Tetracyclines
14.2.1.5. Aminoglycosides
14.2.1.6. Sulfonamides
14.2.1.7. Phenicols
14.2.1.8. Others
14.2.2. Antifungal
14.2.3. Others
14.3. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
14.3.1. MRSA
14.3.2. Pneumonia
14.3.3. Sepsis
14.3.4. Sinusitis
14.3.5. Cellulitis
14.3.6. Otitis
14.3.7. Pharyngitis
14.3.8. Impetigo
14.3.9. Others
14.4. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
14.4.1. Enteral
14.4.2. Parenteral
14.4.3. Others
14.5. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
14.5.1. Hospital Pharmacies
14.5.2. Drug Stores and Retail Pharmacies
14.5.3. Others
14.6. Latin America Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
14.6.1. Brazil
14.6.2.Mexico
14.6.3. Rest of LATAM
14.7. Latin America Gram-positive Bacterial Infections Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Disease
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Gram-positive Bacterial Infections Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Drug Type, 2016–2026
15.2.1. Antibiotic
15.2.1.1. B-Lactam
15.2.1.2. Quinolones
15.2.1.3. Macrolides
15.2.1.4. Tetracyclines
15.2.1.5. Aminoglycosides
15.2.1.6. Sulfonamides
15.2.1.7. Phenicols
15.2.1.8. Others
15.2.2. Antifungal
15.2.3. Others
15.3. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Disease, 2016–2026
15.3.1. MRSA
15.3.2. Pneumonia
15.3.3. Sepsis
15.3.4. Sinusitis
15.3.5. Cellulitis
15.3.6. Otitis
15.3.7. Pharyngitis
15.3.8. Impetigo
15.3.9. Others
15.4. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Route of Administration, 2016–2026
15.4.1. Enteral
15.4.2. Parenteral
15.4.3. Others
15.5. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Distribution Channel, 2016–2026
15.5.1. Hospital Pharmacies
15.5.2. Drug Stores and Retail Pharmacies
15.5.3. Others
15.6. Middle East & Africa Gram-positive Bacterial Infections Market Value Forecast, by Country/Sub-region, 2016–2026
15.6.1. GCC Countries
15.6.2.South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Disease
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player-Competition Matrix(By Tier and Size of companies)
16.2. Market Share Analysis By Tier and Size of the Company(2017)
16.3. Company Profiles
16.3.1. Bayer AG
16.3.2. Pfizer, Inc.
16.3.3. Sanofi
16.3.4. GlaxoSmithKline plc
16.3.5. Merck & Co., Inc.
16.3.6. AstraZeneca
16.3.7. Theravance Biopharma
16.3.8. Bristol-Myers Squibb Company
16.3.9. Novartis AG
16.3.10. Allergan plc.
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers